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Summary 
It is now clear that antigen presenting cells (APCs) do not present all the possible peptides of 
self-proteins to the immune system. What then, is the fate oft cells specific for those self-peptides 
that  escape processing?  In  this  study,  the  COOH-terminal  peptide  (residues  81-104)  of self 
cytochrome c (cyt c) elicited strong autoimmune T  cells,  as well as autoantibodies specific for 
this immunogen. These T cells did not respond to stimulation with the whole self cyt c molecule, 
demonstrating that APCs cannot process and present the self 81-104 peptide. Whereas mice were 
unresponsive to immunization with the whole mouse cyt c molecule, the mouse 81-104 fragment 
together with the whole self-molecule induced and amplified the autoimmune T  cell response 
to sites within the 1-80 peptide. T cells that never contact the relevant self-peptide are functionally 
ignorant. They do not become tolerized or deleted, nor do they normally participate in immune 
responses  to the native whole self-protein,  since APCs cannot  present  the 81-104  peptide. 
S 
uccessful immune responses rely on the intelligence of B 
and T cells to differentiate self from foreign components. 
Self-reactive T cells are controlled either by their elimination 
in the thymus or by the induction  of tolerance in the pe- 
riphery  (1,  2).  Both mechanisms  depend on  the ability of 
APCs to process and present self-peptides in the context of 
MHC molecules, although  it is now apparent  that  not all 
possible peptides from a self-antigen  are presented (3, 4). These 
limitations in processing suggest that T cells specific for some 
determinants on self-proteins may escape tolerance and there- 
fore be a part of the normal repertoire of T cells. The impor- 
tance of such autoreactive T cells in pathological conditions 
may become apparent only under conditions that cause the 
presentation  of normally hidden  self-peptides or when the 
immune system is confronted with foreign molecular mimics. 
Recent studies of autoantigens in SLE have shown that B 
cells elicited with foreign cross-reactive antigen can present self- 
peptides resulting in the priming of autoreactive T cells (5-7; 
Mamula,  M.,  S. Fatehnejad,  and J.  Craft,  manuscript  sub- 
mitted for publication).  The present  study has  identified a 
peptide from a self-protein, cytochrome c (cyt c), capable of 
inducing strong autoreactive T cell responses. This cryptic self- 
peptide, in the presence of the whole self-protein,  breaks T cell 
tolerance to other sites on the self-protein.  These observations 
may have important  implications  in the induction  and ex- 
pansion of the autoimmune T cell responses in human disease. 
Materials and Methods 
Antigens.  Rat heart cyt c (type XX) was purchased from Sigma 
Chemical Co. (St. Louis, MO). Rat cyt c is identical to mouse cyt c 
in amino acid sequence, and is hereafter known as mouse cyt c. 
Human cyt c was the generous gift of Dr. Morris Raichlin (Univer- 
sity of Oklahoma,  Oklahoma City, OK). Both mouse and human 
cytochromes c were repurified by cation exchange chromatography 
as previously described (8). 
Polypeptides encompassing amino acids 81-104 of human cyt c 
or amino acids 37-51, 54-68, 81-95, or 81-104 of mouse cyt c were 
made on a polypeptide synthesizer (RAMPS; DuPont Corp., Wil- 
mington,  DE) or by the Yale University School of Medicine Pro- 
tein and Nucleic Acid Chemistry Facility (New Haven, CT). The 
synthetic polypeptides were analyzed for purity by HPLC and by 
mass spectroscopy. 
Cyanogen bromide (CNBr)-derived polypeptides of mouse cyt c 
were prepared by a modification of a previously described method 
(8). Briefly, repurified whole mouse cyt c was resuspended in 70% 
formic acid and digested for 24 h with CNBr (10:1, CNBr/cyt c 
molar ratio). The digested cyt c was resuspended in sterile PBS for 
use in lymph node cell (LNC) proliferation assays. A fraction of 
the digest was resuspended in 7% formic acid and analyzed by fast 
protein liquid chromatography  (FPLC; Pharmacia LKB Biotech- 
nology, Piscataway, NJ) on a gel filtration column  (Superose 12; 
Pharmacia LKB Biotechnology). CNBr-derived peptides of mouse 
cyt c encompassing 1-80 and 1-65 were purified by FPLC as previ- 
ously described (6). 
Animals.  Immune responses among different murine haplotypes 
were analyzed in mice purchased from The Jackson Laboratory (Bar 
Harbor, ME) or in mice kindly provided by Dr. Charles A. Janeway, 
Jr., (Yale University School of Medicine). The mouse strains used 
included B10.A (5R), B10.A (4R), B10.BR, B10.F, B10/Sn, B10.R 
III,  B10.S, DBA 1, Sm/J, BALB/c, and AKR. Detailed analysis 
of T cell responses to individual polypeptides were performed in 
B10.BR mice. 
Immunization andPmliferaa'on  Assay.  B10.BR mice and the other 
haplotypes  examined were  immunized  with  50 /zg of antigen 
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After 10 d, inguinal, periaortic, and popliteal LNCs were asepti- 
cally collected and washed in Click's EHAA medium supplemented 
with 5% FCS, antibiotics and r-glutamine. The LNCs (5  x  10  s) 
were incubated in flat-bottomed 96-well microtiter wells with and 
without antigen for 3 d. The culture wells were pulsed with 1 #Ci 
[3H]thymidine 18 h before the end of the assay. Experimental wells 
were harvested onto paper with a semiautomatic cell harvester (Ska- 
tron Instruments,  Inc., Sterling, VA), and radioactive counts were 
measured  in  scintillation  fluid  (Beckman  Instruments,  Inc., 
Fullerton, CA). Averages  of duplicate wells were plotted and devi- 
ations from the mean were <10% for all experiments. Purified pro- 
tein derivative (PPD, 20 gg/ml) and negative (no antigen) control 
values are noted in each figure legend. 
Anti-cyt c ELISA.  Serum from B10.BR mice immunized and 
twice boosted with mouse cyt c peptide 81-104 were examined by 
ELISA for binding to whole mouse cyt c and the COOH-terminal 
fragments 81-104 of mouse and human cyt c according to previous 
methods (9). The peptides or whole mouse cyt c was adsorbed to 
the solid phase of  mictotiter plates followed  by a blocking step with 
1% BSA in PBS. Serum dilutions were applied to the plates and 
detected  with  anti-mouse  IgG  alkaline phosphatase conjugate 
(Southern Biotechnology Associates, Birmingham, AL). In some 
assays, dilutions of sera were first incubated for 2 h at 4~  with 
whole cyt c or peptides before their application to ELISA plates. 
Inhibition studies were always performed in conditions of antigen 
excess. Percent inhibition  was calculated as 100  x  [1-(inhibited 
OD/uninhibited OD)]. 
Results  and  Discussion 
The immune system has evolved to ignore self-proteins as 
demonstrated in Fig.  1. T  cells from mice immunized with 
native whole mouse cyt c failed to proliferate in response to 
stimulation with the whole molecule, to a peptide from the 
COOH terminus (81-104),  or to CNBr-derived peptides of 
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Figure 1.  Mice  are unresponsive  to immunization with whole mouse 
cyt c. B10.BR mice were immunized with 50 gg of whole mouse cyt c 
in CFA and standard LN proliferation  assays were performed  at day 10. 
T cells were stimulated with titrations of either whole mouse cyt c, syn- 
thetic fragment 81-104 of mouse cyt c, or total CNBr digests of mouse 
cyt c. The data points represent  the average  of  duplicate  wells  with a devia- 
tion of <1,000 cpm for all experiments.  PPD and negative  control wells 
averaged 86,563 and 3,430 cpm, respectively. 
the whole molecule. In addition, no T lymphocyte or anti- 
body responses (as measured by ELISA) were observed in any 
haplotype (p,  q,  r,  s,  f, v, b,  and d) of mouse immunized 
with its own cyt c (data not shown). 
Mice immunized with human cyt c peptide 81-104 elicited 
T  cells that responded to stimulation with the 81-104 pep- 
tide (Fig. 2 A). Additionally, these T cells responded to stim- 
ulation with the whole human cyt c molecule, suggesting 
that intracellular processing of the native whole human cyt c 
molecule resulted in the expression of a COOH-terminal frag- 
ment on the APC surface, a response that is inhibited by an- 
tibodies to I-E  k (data not shown).  These T  cells were not 
cross-reactive with whole mouse cyt c or its 81-104 fragment. 
In contrast, immunization with fragment 81-104 of mouse 
cyt c elicited T cells that responded only to the mouse 81-104 
fragment (Fig. 2 B) and not to stimulation with whole mouse 
cyt c or the human 81-104 fragment. As a control, T  cells 
could be stimulated with CNBr digests of the whole mouse 
cyt c, a cleavage that generates the 81-104 peptide from the 
whole molecule. This important observation demonstrated 
that the response to the synthetic self-peptide 81-104 was not 
a result of contamination with foreign peptides. Therefore, 
these T  cells could be stimulated by whole mouse cyt c if 
the processing of this molecule is performed in vitro for the 
APC. It is also  apparent that T  cells specific or the mouse 
cyt c 81-104 fragment have not been deleted or tolerized in 
the periphery presumably from the inability of mouse APCs 
to express this fragment. 
The contrasting responses between self and foreign cyt c 
are due to differences in primary amino acid sequences. Mouse 
and human cyt c differ by a total of nine amino acids among 
their 104 total residues, with two differences existing within 
the COOH-terminal peptide (residues 83 and 89). Prelimi- 
nary studies have  demonstrated that changes made in the 
recombinant mouse cyt c protein to the corresponding human 
amino acids at either residues 83 or 89 partially restore the 
ability of APCs to process and present the COOH-terminal 
peptide of the self-antigen (Mamula, M., B. Crump, and E. 
Margoliash, manuscript in preparation). It is not yet clear 
whether amino acids outside the COOH-terminal region are 
critical in processing this peptide of mouse cyt c. 
A previous study has demonstrated that immunization of 
mice with whole mouse cyt c together with various peptides 
along the entire length of foreign (human) cyt c elicited au- 
toreactive T  cells (6). These autoimmune T  cell responses 
were dependent on the presence of a foreign peptide im- 
munogen  or  molecular mimic.  After demonstrating  that 
mouse fragment 81-104 could induce strong T cell responses, 
the ability of this self-determinant to elicit T  cell responses 
to other sites on the self-protein was examined (Fig. 3). Mice 
were immunized with a mixture of whole mouse cyt c and 
the COOH-terminal mouse peptide 81-104. As expected from 
earlier results, T cells from these mice responded to stimula- 
tion with the the 81-104 peptide and CNBr fragments of 
mouse cyt c. In contrast to earlier results using mouse 81-104 
alone as an immunogen, these T  cells now also responded 
to the whole mouse cyt c protein and to purified mouse pep- 
tide 1-80 (Fig. 3). These observations demonstrated that the 
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Figure  2.  Distinct T cell responses of mice immunized with for- 
eign (human) or self-(mouse)  peptide 81-104 of cyt c. B10.BR mice 
were immunized with 50/zg of human cyt c peptide 81-104 (A) or 
mouse peptide 81-104 (B) in CFA at the base of the tail. LN cells 
were stimulated at day 10 with titrations of either whole mouse or 
human cyt c, synthesized peptides 81-104 of mouse or human cyt c, 
or  CNBr  digosts  of whole  mouse  cyt c.  PPD  controls averaged 
>100,000  cpm and negative controls  were <5,878  cpm for all ex- 
periments. 
81-104 self-peptide of cyt c can break T cell tolerance to other 
sites on the self-protein. 
One likely possibility to explain these results is that B cells 
specific for mouse 81-104 peptide also bind and process the 
whole mouse cyt c molecule. Peptides within the first 80 amino 
adds of the protein are then presented in the priming of this 
expanded autoimmune  T  cell response. This mechanism is 
supported by previous studies with cyt c (5, 6) and by studies 
of the antibody responses from mice immunized  with the 
mouse 81-104 fragment (Table 1). Sera from B10.BK mice 
chronically immunized with mouse cyt c 81-104 bound both 
human and mouse 81-104 cyt c fragments in ELISAs, as well 
as binding  the whole molecule  adsorbed to the solid phase 
of microtiter plates. However, the binding  to whole mouse 
cyt c was dependent on partial denaturation of this protein 
since the native protein did not significantly inhibit binding 
in solution phase. Therefore, the release of intracelhlar cyt c 
by tissue pathology or perhaps the apoptosis of LNCs may 
allow sufficient denaturation of the whole protein by extracel- 
Mar proteases in order to be bound, processed, and presented 
by B cells specific for the mouse 81-104 peptide. 
The observations of this study may help explain the diver- 
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Figure  3.  Coimmunization of whole mouse cyt c with pep- 
tide 81-104 elicits T  cells specific for the whole mouse cyt c pro- 
tein. B10.BR mice were immunized with whole mouse cyt c (50 
/~g) together with mouse cyt c peptide 81-104 (50/~g) in CFA 
at the base of the tail  LN proliferation  assays were performed 
at day 10. PPD and negative control wells averaged  84,899 and 
3,544 cpm, respectively. Table  1.  Binding Properties of Anti-Mouse cyt c 81-104 Antisera 
Percent inhibition  with: 
Binding to:  OD  (405)  Ms  81-104  Hu  81-104  Whole  Ms  cyt  c 
Mouse  81-104  0.97  82  66  3 
Human  81-104  1.31  88  92  ND 
Whole Ms cyt c  0.76  72  ND  18 
Serum dilutions (1/100) from mice immunized with mouse cyt c peptide 81-104  were examined by ELISA for binding to mouse or human peptide 
81-104  or to whole mouse cyt c. Serum dilutions were then incubated with 8 gM of antigen before their application to the ELISA plates.  Percent 
inhibition  =  100x  [1  -  inhibited OD/uninhibited OD)]. 
sity of autoimmune  T  cell responses in murine models of 
experimental allergic encephalomyelitis (EAE; 10). Immuni- 
zation with a peptide from foreign (guinea pig) myelin basic 
protein will initiate EAE in mice and dicit T call responses 
to the immunogen. Over the course of disease, the specifidty 
of autoimmune T cells diversifies to several other sites on the 
mouse myelin basic protein (10).  This observation demon- 
strates that  the self-protein has entered into the expanding 
autoimmune T  ceU response in the mouse. It is likely that 
the initial  immunization  with foreign peptide had elicited 
B cells that bound the self-myelin basic protein.  The B cells 
then processed and presented a variety of other self-peptides 
in the priming of autoreactive T calls that were observed over 
time. In similar studies, MRL lpr/lpr mice (the routine model 
of human SLE) immunized with mouse cyt c 81-104 exhibited 
spontaneous expansion of autoreactive T cell specificity to sites 
within the 1-80 peptide over the course of several months (M. 
Mamula,  unpublished observations). This diversified T  cell 
response occurred only after clinical  symptoms of SLE ap- 
peared in the mouse. This response also suggested that self 
cyt c released by tissue pathology had contributed to the au- 
toimmune response. In either of these examples, it is not yet 
clear how the diversity of the autoreactive T  cell response 
may correlate with  the severity of disease. 
This study has identified a subset of autoreactive T  cells 
that are functionally ignorant in vivo. Such cells are allowed 
to exist in the host because of the processing properties of 
self-proteins rather than secondary defects in mechanisms of 
tolerance or deletion. The consequences of activation of these 
T cells may not be completely known until mechanisms that 
may interfere with normal processing functions of self pro- 
teins are understood. Dissection of these processes may help 
decipher the early events in the initiation  of autoimmune 
disease. 
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